prompt1 : extract information from  breast pathology report. List the histological classification, i.e. type of cancer or DCIS, subtype, description of any necrosis, any mention of tumor infiltrating lymphocytes,  histological grade, nuclear grade,  lymphovascular invasion, calcification, receptor status, IHC and any other ancillary testing results.  List out and expand the main points.
prompt2 : The report is - Subtype Her2, SPECIMENS: A. EXCISION LEFT BREAST. B. LEFT AXILLARY SKIN TAG. C. LEFT AXILLA S.L.N. #1. D. LEFT AXILLA S.L.N. #2. E. LEFT AXILLARY CONTENTS. SPECIMEN(S): A. EXCISION LEFT BREAST. B. LEFT AXILLARY SKIN TAG. C. LEFT AXILLA S.L. N. #1. D. LEFT AXILLA S.L.N. #2. E. LEFT AXILLARY CONTENTS. GROSS DESCRIPTION: A. EXCISION LEFT BREAST. Received fresh labeled with the patient's identification, "Excision Left Breast" is a 130g, 8 x 11 x 4cm oriented. (Single-Anterior, Double-Lateral, Triple-Superior) left lumpectomy with 5 x 2 cm tan pink unremarkable skin ellipse. Ink Code: Anterior-Yellow, Posterior-Black, Medial-Green, Lateral-Red, Superior-Blue, Inferior-Orange. The. specimen is serially sectioned from medial to lateral into 8 slices to reveal a 3 x 3 x 2.3cm gray white firm ill defined. mass, 0.5cm from the closest anterior-superior margins in slices 3-6. A portion of the specimen is submitted for. tissue procurement. Representative sections are submitted as follows: A1: medial margin slice 1. A2-A3: superior margin slice 2. A4: area next to mass slice 2. A5: skin slice 3. A6: mass with anterior margin slice. 3. A7: mass with deep margin slice 3. A8: mass with anterior margin slice 3. A9: mass with deep margin slice 3. A10: anterior/superior margin slice 4. A11: superior margin slice 4. A12: mass with anterior margin slice 4. A13: mass with deep margin slice 4. A14: mass with anterior margin slice 4. A15: mass with anterior/inferior margin slice 4. A16: mass slice 4. A17: deep margin slice 4. A18: deep/inferior margin slice 4. A19: mass with anterior margin slice 5. A20: superior margin slice 5. A21: mass slice 5. A22: mass with deep margin slice 5. A23-A24: anterior margin slice 5. A25: mass slice 5. A26-A27: mass with deep margin slice 5. A28-A29: mass with anterior margin slice 6. A30-A31: mass slice 6. A32: deep margin slice 6. A33: next to mass slice 7. A34-A35: deep margin slice 7. A36: lateral margin slice 8. B. LEFT AXILLARY SKIN TAGS. Received in formalin are two polypoid skin tags, 0.1 and 0.3 cm in diameter. Submitted entirely in cassette B1. C. LEFT AXILLARY SLN #1. Received fresh is a tan pink lymph node 1.0 x 0.6 x 0.3cm. The specimen is bisected and a touch prep is taken. Toto. C1. D. LEFT AXILLARY SLN #2. Received fresh is a tan pink lymph node 1.5 x 1.2 x 0.6cm. The specimen is bisected and a touch prep is taken. Toto. D1. E. LEFT AXILLARY CONTENTS. Received in formalin is a piece of yellow-tan adipose tissue, 9.5 x 0.5 x 2.7 cm. Multiple lymph nodes are identified. ranging in size from 0.1 to 2.7 cm. The larger lymph nodes are bisected and have variegated pink-tan coloration. There is a blood vessel, 0.9 cm and the length and 0.4 cm in diameter, which is clipped at both ends. It contains. blood clot. Specimen is submitted entirely: E1-E2: 6 lymph nodes each. E3-E5: 2 lymph nodes each. E6-E8: 1 lymph node each. E9-E10: 1 lymph node. E11-E25: remainder of soft tissue. DIAGNOSIS: A. BREAST, LEFT, WIDE LOCAL EXCISION: - INVASIVE DUCTAL CARCINOMA, POORLY DIFFERENTIATED. (SBR GRADE 3). - INVASIVE CARCINOMA MEASURES 3 CM IN GREATEST DIMENSION. - MARGINS, FREE OF TUMOR. - LYMPHVASCULAR INVASION IS PRESENT. - DUCTAL CARCINOMA IN SITU (DCIS), SOLID AND MICROPAPILLARY. TYPES, NUCLEAR GRADE 3, WITH NECROSIS AND MICROCALCIFICATIONS. DCIS IS WITHIN 3 MM OF THE SUPERIOR MARGIN AND IS WITHIN. 4 MM OF THE POSTERIOR MARGIN. - SKIN, NO TUMOR SEEN. B. AXILLA, LEFT, SKIN TAG, EXCISION: - ACROCHORDONS. C. SENTINEL LYMPH NODE #1, LEFT AXILLA, BIOPSY: - METASTATIC CARCINOMA (0.3 CM IN SIZE) TO ONE LYMPH NODE (1/1). D. SENTINEL LYMPH NODE #2, LEFT AXILLA, BIOPSY: - METASTATIC CARCINOMA (1.5 CM IN SIZE) TO ONE LYMPH NODE WITH. FOCAL EXTRANODAL EXTENSION (1/1). E. AXILLARY CONTENTS, LEFT, DISSECTION: - METASTATIC CARCINOMA (0.8 CM IN SIZE) TO ONE OF 22 LYMPH NODES. (1/22). SYNOPTIC REPORT - BREAST. Specimen Type: Excision. Needle Localization: Laterality: Left. Invasive Tumor: Present. Multifocality: No. WHO CLASSIFICATION. Invasive ductal carcinoma, NOS 8500/3. Tumor size: 3cm. Tumor Site: Lower inner quadrant. Margins: Negative. Distance from closest margin: 0.5cm. anterior. Tubular Score: 3. Nuclear Grade: 3. Mitotic Score: 3. Modified Scarff Bloom Richardson Grade: 3. Necrosis: Absent. Vascular/Lymphatic Invasion: Present. Lobular neoplasia: None. Lymph nodes: Sentinel lymph node and axillary dissection. Lymph node status: Positive 3 /24 Extranodal extension. DCIS present. Margins uninvolved by DCIS. DCIS Quantity: Estimate 40%. DCIS Type: Solid. Micropapillary. DCIS Location: Associated with invasive tumor. Nuclear grade: High. Necrosis: Present. Location of CA++: DCIS. Stroma. ER/PR/HER2 Results. ER: Positive. PR: Positive. HER2: Pending. Pathological staging (pTN): pT2N1. CLINICAL HISTORY: 5cm tumor-Invasive Cancer on Core Bx. Lower Inner Quadrant Left Breast. PRE-OPERATIVE DIAGNOSIS: Left breast cancer. INTRAOPERATIVE CONSULTATION: A. GROSS INSPECTION: 3cm mass, 0.5cm from the closest Anterior margin. TPC-TPD: Positive for Adenocarcinoma. Diagnoses called to Dr. at. (A) and. (C-D) by Dr. ADDENDUM: SYNOPTIC REPORT - BREAST HER-2 RESULTS. Specimen: Surgical Excision. Block Number: A16. Interpretation: POSITIVE. Intensity: % Tumor Staining: 100%. Fish Ordered: No. METHODOLOGY: Tissue was fixed in 10% neutral buffered formalin for no less than 8 and nn longer than 24 hours. Her2 analysis. was performed using the FDA approved Dako HercepTest (TM) test kit. using rabbit anti-. human HER2. This assay was not modified. External kit-slides provided by the manufacturer (cell lines with high,. low and negative HER2 protein expression) and in-house known HER2 amplified control tissue were evaluated along. with the test tissue. Adequate, well preserved, clear-cut invasive carcinoma was identified for HER2 evaluation. Interpretation of the HER2 immunohistochemical stain is guided by published results in the medical literature,. information provided by the reagent manufacturer and by internal review of staining performance. This assay has been validated according to the 2007 joint recommendations and guidelines from ASCO. and. CAP. and from the NCCN HER2 testing in Breast Cancer Task Force. The Pathology Department takes full responsibility. for this test's performance. Microscopic/Diagnostic Dictation Pathologist,. Final Review: Pathologist,. Final Review: Pathologist. Final: Pathologist,. Addendum: Pathologist. Addendum Final: Pathoiogist, 1.

expanded version (tokens=2340) : 
 Histological Classification:
- Invasive Ductal Carcinoma, Poorly Differentiated (SBR Grade 3)
- Ductal Carcinoma In Situ (DCIS), Solid and Micropapillary Types, Nuclear Grade 3, with Necrosis and Microcalcifications

Subtype: HER2+

Necrosis: Present in DCIS

Tumor Infiltrating Lymphocytes: Not mentioned

Histological Grade: SBR Grade 3

Nuclear Grade: 3

Lymphovascular Invasion: Present

Calcification: Present in DCIS

Receptor Status: ER-positive, PR-positive, HER2+

Ancillary Testing Results: HER2 immunohistochemical stain was performed using the Dako HercepTest and showed 100% tumor staining, indicating a positive HER2 result.

Additional findings:
- The invasive carcinoma measures 3 cm in greatest dimension
- The margins are free of tumor
- The DCIS is within 3 mm of the superior margin and within 4 mm of the posterior margin
- Metastatic carcinoma was found in 1/1 sentinel lymph node and 1/22 axillary lymph nodes with focal extranodal extension

Overall pathological staging is pT2N1.

prompt : Please generate a succinct report in 75 words from the above information. Exclude any filler words or sentences. If something is not mentioned or specified, exclude it from the report. Low verbosity.

final output (tokens=2520) : 
 Left breast pathology report shows a poorly differentiated HER2+ invasive ductal carcinoma measuring 3cm. Ductal carcinoma in situ (DCIS) is also present within 3mm of the superior margin and within 4mm of the posterior margin. Necrosis and calcification are present in DCIS. Lymphovascular invasion is seen, and lymph node involvement includes metastatic carcinoma in both sentinel and axillary lymph nodes with focal extranodal extension. Margin status is free of tumor. ER and PR are positive, HER2 immunohistochemical stain was positive with 100% tumor staining. Overall pathological staging is pT2N1.

